

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season**

as of April 30, 2020, June 30, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	1 <sup>a</sup> (0.14%)	26 <sup>b</sup> (1.4%)	26 <sup>b</sup> (1.4%)	0	0	29 (100%)	0	0	0	0	0	10 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	738	1,892	1,892	298	298	29	49	64	64	64	64	10	27	77	77	77	77
<b>Number of viruses reported</b>	4,599						120						519				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 1

<sup>b</sup> Patients without treatment 18